The global contingent heart disease market is anticipated to grow at a CAGR of nearly 9.1% during the forecast period (2021-2027). Key companies across the globe are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launch, and product innovation to remain competitive in the marketplace. For instance, in November 2020, Abbott laboratories launched its clip delivery system, which is a minimally invasive heart valve repair device to treat mitral regurgitation in India. The clip device repairs leaky mitral valves without open-heart surgery and is delivered to the heart through a vein in the leg.
Browse the full report description of "Global Congenital Heart Diseases Market, By Defect Type (Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, By Diagnosis (Echocardiogram, Chest X-ray, MRI, and Others), By Treatment (Medications, Implantable Heart Device, Catheter Procedure, Open Heart Surgery, and Heart Transplant), End-Users (Hospitals and Clinics, Diagnostic Centers, Others), and Forecast Period 2021-2027" at https://www.omrglobal.com/industry-reports/congenital-heart-diseases-market
Apart from this, in March 2021, the US Food and Drug Administration (FDA) approved first of its kind heart valve which takes the open heart part out of certain open-heart surgeries. The Medtronic harmony transcatheter pulmonary valve provided by the company is the first pulmonary heart valve in the world to be approved for patients with congenital heart disease without requiring open-heart surgery. Additionally, in January 2019, Siemens Healthineers introduced its portfolio in MRI, X-ray machines ultrasound, cutting edge technology with CT scanners, and digital solutions in Chandigarh, India. Syngo virtual cockpit by Seimens Healthineers can be used by medical staff for more sophisticated examination for MRI and ct scans.
Besides, in November 2020, Viatris Inc. launched a combination of Mylan N. V AND Pfizers Upjohn's business. The combination will allow Viatris, to leverage scientific, manufacturing, and distribution expertise with proven regulatory, medical and global commercial capabilities to deliver high-quality medicine to patients in over 165 countries and territories. Furthermore, in November 2020, Mylan officially announced that the company is stopping its operations and will be a part of Viatris Inc. These kinds of partnerships are offering an opportunity for the introduction of more innovative devices, drugs, and diagnostic tools for accurate diagnosis and treatment of the condition. This, in turn, is expected to provide enormous opportunity for the market growth.
Market Coverage
o By Defect Type
o By Diagnosis
o By Treatment
o By End-User
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Contingent Heart Disease Market Report Segment
By Defect Type
By Diagnosis
By Treatment
By Diagnosis
Global Contingent Heart Disease Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/congenital-heart-diseases-market